Strategies for Clinical Imaging in Diabetes

Event Details

You may also be interested in the Imaging the Pancreas in Diabetes, and Benign and Malignant Exocrine Pancreatic Disease meeting.

Background

The ability to noninvasively image the cell types of the pancreatic islet and their function, particularly the beta cell, would allow diabetes researchers to observe and learn about the natural history of diabetes in living human beings. Most of the information we have currently about the fate of the insulin-producing cells comes from single snapshots taken in cadaver pancreas from people in various stages of diabetes. At this time, there are several promising imaging agents in various stages of development and validation.

Objectives

This workshop is designed to provide a forum for discussion of the state of the art of in vivo imaging of the pancreatic islet beta cell mass and function, and the next steps toward this important goal.

Organizing Committee

Gary Cline, Yale University
Martin Gotthardt, Radboud University Nijmegen, Netherlands
Paul E. Harris, Columbia University
Anna Moore, Michigan State University
Alvin Powers, Vanderbilt University
Dana Anderson, NIDDK, NIH
Olivier Blondel, NIDDK, NIH
Maren R. Laughlin, NIDDK, NIH
Lalitha Shankar, NCI, NIH

Registration Deadline

January 5, 2020

Agenda

You may also be interested in the Imaging the Pancreas in Diabetes, and Benign and Malignant Exocrine Pancreatic Disease meeting.

January 15, 2020

8:00 a.m. – 8:05 a.m.

Workshop Goals
Maren Laughlin, Ph.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Keynote: Clinical Perspective

8:05 a.m. – 8:40 a.m.

How Could Imaging of the Endocrine Pancreas Illuminate the Natural History of Diabetes and Improve Clinical Care?
Al Powers, M.D., Vanderbilt University

Session One: State of the Art—Imaging Beta Cell and Islet Mass in People

8:30 a.m. – 8:45 a.m.

Exendin Analogues and GLP1R Imaging
Martin Gotthardt, M.D., Ph.D., Nijmegen University, The Netherlands

8:45 a.m. – 9:00 a.m.

[18F]FP-DTBZ and VMAT2 Imaging
Paul Harris, Ph.D., Columbia University

9:00 a.m. – 9:15 a.m.

[11C]-(+)-PHNO and D2R/D3R Imaging
Gary Cline, Ph.D., Yale University

9:15 a.m. – 9:30 a.m.

GPR44 and DGCR2 Imaging
Olof Eriksson, Ph.D., M.Sc., Uppsala University, Sweden

9:30 a.m. – 9:45 a.m.

FXYD2ya and DPP6 Imaging
Decio Eizirik, M.D., Ph.D., Universite Libre de Bruxelles, Belgium

9:45 a.m. – 10:20 a.m.

Panel Discussion

10:20 a.m. – 10:40 a.m.

Break

10:40 a.m. – 11:00 a.m.

Imaging in Live Pancreas Slices
Stephan Speier, Ph.D., Technical University Dresden, Germany

11:00 a.m. – 11:20 a.m.

Improved PET Sensitivity/Spatial Resolution on the Horizon
Simon Cherry, Ph.D., University of California, Davis

11:20 a.m. – 11:40 a.m.

Perspectives in Radiochemistry and Probe Development
Richard Carson, Ph.D., Yale University

11:20 a.m. – 12:10 p.m.

Panel Discussion

12:10 p.m. – 1:00 p.m.

Working Lunch (Conference Rooms A/B)
Moderator: Alvin Powers, M.D., Vanderbilt University
What are the Roadblocks to Beta Cell Imaging? What Is the Source of Background Signal in T1D? Are Current Approaches Sufficiently Quantitative? How Can Imaging Technology Developments Impact the Field?

Session Two: State of the Art—Islet Imaging in Disease Progression and Therapy in People

1:00 p.m. – 1:45 p.m.

Data-driven Discussion: Islet Transplantation, Therapy and Imaging
Philip Streeter, Ph.D., Oregon Health Science Center
Jeff Bulte, Ph.D., M.S., Johns Hopkins University
Martin Gotthardt, M.D., Ph.D., Nijmegen University, The Netherlands
Fouad Kandeel, M.D., Ph.D., City of Hope Medical Center
Alvin Powers, M.D., Vanderbilt University
Anna Moore, Ph.D., Michigan State University

1:45 p.m. – 2:30 p.m.

Data-driven Discussion: Safety Issues Associated with PET Imaging in Diabetes
Martin Gotthardt, M.D., Ph.D., Nijmegen University, The Netherlands
Olof Eriksson, Ph.D., M.Sc., Uppsala University, Sweden
Richard Carson, Ph.D., Yale University
Olle Korsgren, M.D., Ph.D., Uppsala University, Sweden
Alvin Powers, M.D., Vanderbilt University

2:30 p.m. – 2:50 p.m.

Cell-based Therapies in the Pipeline
Jason Gaglia, M.D., Semma Therapeutics and Joslin Diabetes Center

Discussion: Next Steps
Moderator: Maren Laughlin, Ph.D., NIDDK

2:50 p.m. – 3:30 p.m.

Round Table Discussion: Where Do We Go from Here?
Which Approaches Are Ready for Validation? How Do We Go about It? What Clinical Studies Are Needed? Where Do We Go from Here?

3:30 p.m.

Adjournment

Abstracts

Submission Deadline

December 13, 2019

Submitting Abstracts

All abstracts must be submitted via email to Maren Laughlin and Gizem Fern.

Abstracts submissions are welcome which describe previously unpublished and unpresented work related to the mission and scope of the workshop. The work of selected abstracts will be presented in poster session, with a limited number invited to provide oral presentations during the workshop. Selected abstracts will be included in the program folder. Posters will be displayed on 4 x 6 ft poster boards.

Formatting Requirements

Please follow the instructions below to format an abstract.

The abstract should be a SINGLE PAGE MS Word document typed single-spaced using Times New Roman font. Use 0.5 inch margins at top and bottom of the page and 1.0 inch margins on the sides. Everything but the title should be in normal, 12-point font.

• The abstract’s title should be Bold, 16-Point, Title Case font and should clearly represent the nature of the investigation.
• On the line after the title, list the author’s first and last names, degree, affiliation, city, state, and country.
• Separate multiple authors with a semicolon; and underline the primary author’s name (one primary author per abstract).
• Skip one (blank) line between the title and the body of the abstract.
• Include (and label) sections on INTRODUCTION, METHODS, RESULTS, and CONCLUSIONS but do not use separate paragraphs for these sections.
• The abstract file name should follow this format: Last Name of primary author_First Word of Title (e.g., Zucker_Effects).
• Use of standard abbreviations is desirable (e.g., BMI), as well as standard symbols for units of measure (e.g., kg, g, mg, mL, L, and %). Place any special or unusual abbreviations in parentheses after the full word the first time that it appears. Use numerals to indicate numbers except to begin sentences. Do not use subheadings (e.g., Methods, Results).
• Simple tables, representative figures or graphs may be included; however, they must fit within the designated abstract space of one page.